Book contents
- 50 Big Debates in Reproductive Medicine
- Series page
- 50 Big Debates in Reproductive Medicine
- Copyright page
- Contents
- Contributors
- Foreword
- Introduction
- Section I Limits for IVF
- Section II IVF Add-ons
- Section III The Best Policy
- Section IV Embryology
- Section V Ethics and Statistics
- Section VI Male-factor Infertility
- Section VII Genetics
- Section VIII Ovarian Stimulation
- Section IX Hormones and the Environment
- 45A Metformin Is an Effective Treatment for Infertility Associated with Anovulatory PCOS
- 45B Metformin Is an Effective Treatment for Infertility Associated with Anovulatory PCOS
- 46A Laparoscopic Ovarian Drilling Should Be Performed for CC-Resistant PCOS
- 46B Laparoscopic Ovarian Drilling Should Be Performed for CC-Resistant PCOS
- 47A Asymptomatic Polycystic Ultrasound Appearance of the Ovary Is Favourable for IVF Outcome
- 47B Asymptomatic Polycystic Ultrasound Appearance of the Ovary Is Favourable for IVF Outcome
- 48A Ultrasound Monitoring Is Not Required for Letrozole Treatment
- 48B Ultrasound Monitoring Is Not Required for Letrozole Treatment
- 49A Progesterone Levels Should Be Measured on the Day of hCG Administration
- 49B Progesterone Levels Should Be Measured on the Day of hCG Administration
- 50A Progesterone Treatment Does Not Help Recurrent Miscarriage Patients
- 50B Progesterone Treatment Does Not Help Recurrent Miscarriage Patients
- 51A The Microbiome Environment Influences IVF Results
- 51B The Microbiome Environment Influences IVF Results
- Index
- References
47A - Asymptomatic Polycystic Ultrasound Appearance of the Ovary Is Favourable for IVF Outcome
For
from Section IX - Hormones and the Environment
Published online by Cambridge University Press: 25 November 2021
Book contents
- 50 Big Debates in Reproductive Medicine
- Series page
- 50 Big Debates in Reproductive Medicine
- Copyright page
- Contents
- Contributors
- Foreword
- Introduction
- Section I Limits for IVF
- Section II IVF Add-ons
- Section III The Best Policy
- Section IV Embryology
- Section V Ethics and Statistics
- Section VI Male-factor Infertility
- Section VII Genetics
- Section VIII Ovarian Stimulation
- Section IX Hormones and the Environment
- 45A Metformin Is an Effective Treatment for Infertility Associated with Anovulatory PCOS
- 45B Metformin Is an Effective Treatment for Infertility Associated with Anovulatory PCOS
- 46A Laparoscopic Ovarian Drilling Should Be Performed for CC-Resistant PCOS
- 46B Laparoscopic Ovarian Drilling Should Be Performed for CC-Resistant PCOS
- 47A Asymptomatic Polycystic Ultrasound Appearance of the Ovary Is Favourable for IVF Outcome
- 47B Asymptomatic Polycystic Ultrasound Appearance of the Ovary Is Favourable for IVF Outcome
- 48A Ultrasound Monitoring Is Not Required for Letrozole Treatment
- 48B Ultrasound Monitoring Is Not Required for Letrozole Treatment
- 49A Progesterone Levels Should Be Measured on the Day of hCG Administration
- 49B Progesterone Levels Should Be Measured on the Day of hCG Administration
- 50A Progesterone Treatment Does Not Help Recurrent Miscarriage Patients
- 50B Progesterone Treatment Does Not Help Recurrent Miscarriage Patients
- 51A The Microbiome Environment Influences IVF Results
- 51B The Microbiome Environment Influences IVF Results
- Index
- References
Summary
The significant advances in ultrasound technology have resulted in an increase in the prevalence of PCO morphological ultrasonographic criteria diagnosis. These patients have a live birth rate after undergoing up to three cycles of IVF treatment that is 82% higher than women with normal ovaries, requiring fewer ampules of gonadotrophins, producing more follicles and viable oocytes with similar fertilisation and miscarriage rates. Since these women exhibit an exaggerated response to gonadotrophin therapy regardless of COH protocol, the risk remains the increased prevalence of OHSS. Since no COH protocol is superior to manage these patients, protocols that trigger oocyte maturation with a GnRH agonist, with or without a ‘freeze-all’ approach, should be encouraged. Therefore, it is important that every patient undergoing IVF has a baseline ultrasound scan, antral follicle count and AMH levels as well as an assessment of ovarian morphology prior to ART treatments in order to assess risk and reduce complications.
Keywords
- Type
- Chapter
- Information
- 50 Big Debates in Reproductive Medicine , pp. 244 - 246Publisher: Cambridge University PressPrint publication year: 2021
References
Catteau-Jonard, S, Bancquart, J, Poncelet, E, Lefebvre-Maunoury, C, Robin, G, Dewailly, D. Polycystic ovaries at ultrasound: normal variant or silent polycystic ovary syndrome? Ultrasound Obstet Gynecol. 2012 Aug;40(2):223–9.CrossRefGoogle ScholarPubMed
Mizrachi, Y, Horowitz, E, Farhi, J, Raziel, A, Weissman, A. Ovarian stimulation for freeze-all IVF cycles: a systematic review. Hum Reprod Update. 2020 Jan 1;26(1):118–35.CrossRefGoogle ScholarPubMed
Engmann, L, Sladkevicius, P, Agrawal, R, et al. The pattern of changes in ovarian stromal and uterine artery blood flow velocities during IVF treatment and its relationship with outcome of the cycle. Ultrasound Obstet Gynecol. 1999 Jan;13(1):26–33.CrossRefGoogle ScholarPubMed
Kim, YJ, Ku, SY, Jee, BC, et al. A comparative study on the outcomes of in vitro fertilization between women with polycystic ovary syndrome and those with sonographic polycystic ovary-only in GnRH antagonist cycles. Arch Gynecol Obstet. 2010 Aug;282(2):199–205.CrossRefGoogle ScholarPubMed
Engmann, L, Maconochie, N, Sladkevicius, P, Bekir, J, Campbell, S, Tan, SL. The outcome of in-vitro fertilization treatment in women with sonographic evidence of polycystic ovarian morphology. Hum Reprod. 1999 Jan;14(1):167–71.CrossRefGoogle ScholarPubMed
Selçuk, S, Özkaya, E, Eser, A, et al. Characteristics and outcomes of in vitro fertilization in different phenotypes of polycystic ovary syndrome. Turk J Obstet Gynecol. 2016 March; 13(1):1–6.CrossRefGoogle ScholarPubMed